Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

AZ/Merck's Lynparza improves survival in certain prostate cancers

AZ/Merck's Lynparza improves survival in certain prostate cancers

already begun using Lynparza following progression of their disease.

Latest news

More from news
Approximately 1 fully matching, plus 294 partially matching documents found.

Latest Intelligence

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    Despite the significant anecdotal evidence, an initial study of Kaletra in China demonstrated some disappointing results; it did not seem to have any significant effect on disease progression. ... Infectious disease expert Lindsey R Braden and NEJM editor

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... If people are hoping for any of the molecules under investigation to be a

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    According to the study, the blood test is able to identify this protein 20 years before the symptoms of the disease start to present. ... Alzheimer’s R&D has had to diversify as companies and researchers become increasingly aware that the disease has a

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    applications in pharma and real-world ML/AI platforms for scalable disease diagnostics, progression and treatment. ... We’re going to work with the NHS to eliminate this disease in the UK.

  • The first, my last, my everything The first, my last, my everything

    In a widespread shift from volume to value, around 80% of molecules in development at present are in oncology or rare disease. ... In the past, industry has taken a traditional view of patient value, typically basing it on clinical outcomes and disease

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 17 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics